Physical therapy management of infants and children with hypophosphatasia

Molecular Genetics and Metabolism

Volumn 119, Issue 1-2, 2016, Pages 14-19

  Phillips, Dawn ^a   Case, Laura E ^b   Griffin, Donna ^c   Hamilton, Kim ^d   Lara, Sergio Lerma ^e   Leiro, Beth ^f   Monfreda, Jessica ^g   Westlake, Elaine ^g,h   Kishnani, Priya S ⁱ  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (United States)

^d HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f Functional Outcomes Consultant   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h CHILDREN S HOSPITAL OAKLAND   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fractures, spontaneous; Gait; Hypophosphatasia; Motor skills; Musculoskeletal pain; Physical therapy specialty

Indexed keywords

PHOSPHATASE; RECOMBINANT ENZYME;

ADAPTIVE EQUIPMENT; CHILD; CHILD DEVELOPMENT; CLINICAL FEATURE; ENVIRONMENT; ENZYME REPLACEMENT; HUMAN; HYPOPHOSPHATASIA; INFANT; NOTE; PHYSICAL MOBILITY; PHYSIOTHERAPY; PRIORITY JOURNAL; REHABILITATION EQUIPMENT; ADOLESCENT; FEMALE; GAIT; MALE; MOTOR PERFORMANCE; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL SYSTEM MALFORMATION; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FRACTURES, SPONTANEOUS; GAIT; HUMANS; HYPOPHOSPHATASIA; INFANT; MALE; MOTOR SKILLS; MUSCULOSKELETAL ABNORMALITIES; MUSCULOSKELETAL PAIN; PHYSICAL THERAPY MODALITIES;

EID: 84977126875     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2016.06.010     Document Type: Note

References (24)

1. [1] Whyte, M.P., Hypophosphatasia. Thakker, R., Whyte, M.P., Eisman, J., Igarashi, T., (eds.) Genetics of Bone Biology and Skeletal Disease, 2013, Academic Press, San Diego, 337–360.
2. [2] Hofmann, C., Girschick, H.J., Mentrup, B., Graser, S., Liese, J., Jakob, F., Clinical aspects of hypophosphatasia: an update. Clin. Rev. Bone Miner. Metab. 11 (2013), 60–70.
3. [3] Rockman-Greenberg, C., Hypophosphatasia. Pediatr. Endocrinol. Rev. 10:Suppl. 2 (2013), 380–388.
4. [4] Mornet, E., Yvard, A., Taillandier, A., Fauvert, D., Simon-Bouy, B., A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann. Hum. Genet. 75:3 (2011), 439–445.
5. [5] Bianchi, M.L., Hypophosphatasia: an overview of the disease and its treatment. Osteoporos. Int. 26:12 (2015), 2743–2757.
6. [6] Leung, E.C., Mhanni, A.A., Reed, M., Whyte, M.P., Landy, H., Greenberg, C.R., Outcome of perinatal hypophosphatasia in Manitoba Mennonites: a retrospective cohort analysis. JIMD Rep. 11 (2013), 73–78.
7. [7] Whyte, M.P., Zhang, F., Wenkert, D., McAlister, W.H., Mack, K.E., Benigno, M.C., Coburn, S.P., Wagy, S., Griffin, D.M., Ericson, K.L., et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone 75 (2015), 229–239.
8. [8] Beck, C., Morbach, H., Stenzel, M., Collman, H., Schneider, P., Girschick, H.J., Hypophosphatasia - recent advances in diagnosis and treatment. Open Bone J. 1 (2009), 8–15.
9. [9] STRENSIQ, (Asfotase Alfa) [Prescribing Information]. 2015, Alexion Pharmaceuticals Inc., Cheshire, CT.
10. [10] Whyte, M.P., Greenberg, C.R., Salman, N.J., Bober, M.B., McAlister, W.H., Wenkert, D., Van Sickle, B.J., Simmons, J.H., Edgar, T.S., Bauer, M.L., et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N. Engl. J. Med. 366:10 (2012), 904–913.
11. [11] Whyte, M.P., Rockman-Greenberg, C., Ozono, K., Riese, R., Moseley, S., Melian, A., Thompson, D., Bishop, N., Hofmann, C., Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J. Clin. Endocrinol. Metab. 101:1 (2016), 334–342.
12. [12] Madson, K., Rockman-Greenberg, C., Melian, A., Moseley, S., Reeves, A.L., Odrljin, T., Whyte, M.P., Asfotase alfa: sustained improvements in hypophosphatasia-related rickets, physical function, and pain during 3 years of treatment of severely affected children. Annual Meeting of the American Society for Bone and Mineral Research; September 12–15, 2014, 2014, Houston, TX.
13. [13] Whyte, M.P., Madson, K.L., Phillips, D., Reeves, A.L., McAlister, W.H., Yakimoski, A., Mack, K.E., Hamilton, K., Kagan, K., Fujita, K.P., et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight, 2016, 10.1172/jci.insight.85971 (Epub ahead of print).
14. [14] Phillips, D., Griffin, D., Przybylski, T., Morrison, E., Reeves, A.L., Vallee, M., Fujita, K.P., Madson, K.L., Whyte, M.P., Gait assessment in children with childhood hypophosphatasia: impairments in muscle strength and physical function. Endocr. Rev., 36, 2015, 2.
15. [15] Deitz, J.C., Kartin, D., Kopp, K., Review of the Bruininks-Oseretsky Test of motor proficiency, second edition (BOT-2). Phys. Occup. Ther. Pediatr. 27:4 (2007), 87–102.
16. [16] Bayley, N., Bayley scales of infant and toddler development - third edition. J. Psychoeduc. Assess. 25:2 (2006), 180–198.
17. [17] Palisano, R.J., Kolobe, T.H., Haley, S.M., Lowes, L.P., Jones, S.L., Validity of the Peabody Developmental Gross Motor Scale as an evaluative measure of infants receiving physical therapy. Phys. Ther. 75:11 (1995), 939–948 (discussion 948-951).
18. [18] D. Phillips, S. Moseley, T. Odrljin, K.P. Fujita, A. Reeves, A. Yakimoski, K.L. Madson, C. Rockman-Greenberg, M.P. Whyte: Significantly improved muscle strength, running speed, and agility in children with hypophosphatasia treated with asfotase alfa. In: ENDO 2015 (Endocrine Society's 97th Annual Meeting and Expo), March 5–8, 2015; San Diego, CA.
19. [19] Hummel, P.A., Puchalski, M.L., Creech, D., Weiss, M.G., N-PASS: neonatal pain, agitation and sedation scale - reliability and validity. Anestesia Pediatrica e Neonatale, 2(6), 2004.
20. [20] Merkel, S.I., Voepel-Lewis, T., Shayevitz, J.R., Malviya, S., The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr. Nurs. 23:3 (1997), 293–297.
21. [21] Merkel, S., Malviya, S., Pediatric pain, tools, and assessment. J. Perianesth. Nurs. 15:6 (2000), 408–414.
22. [22] Hoyer-Kuhn, H., Semler, O., Stark, C., Struebing, N., Goebel, O., Schoenau, E., A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J. Musculoskelet. Neuronal Interact. 14:4 (2014), 445–453.
23. [23] Semler, O., Fricke, O., Vezyroglou, K., Stark, C., Stabrey, A., Schoenau, E., Results of a prospective pilot trial on mobility after whole body vibration in children and adolescents with osteogenesis imperfecta. Clin. Rehabil. 22:5 (2008), 387–394.
24. [24] Madson, K.L., Phillips, D., Rockman-Greenberg, C.R., Reeves, A., Fujita, K.P., Moseley, S., Thompson, D., Whyte, M.P., Improved functional mobility with asfotase alfa treatment in childhood hypophosphatasia. Annual Meeting of the American Society for Bone and Mineral Research; October 9–12, 2015; Seattle, WA, 2015.